Regulatory Submission

DBV plans BLA for peanut patch in toddlers as safety trial keeps enrolling

DBV Technologies is preparing an accelerated-approval submission for Viaskin Peanut in 1-to-3-year-olds while the supporting safety study continues recruiting toward its own November 2026 completion.

By AppliedXLJuly 13, 2026Trial NCT07003919

Executive Summary

DBV Technologies is targeting the second half of 2026 to file for accelerated approval of its peanut allergy patch in a younger pediatric group than it has previously sought to treat.
The safety study underpinning that filing is still recruiting toward its enrollment target and is not due to reach its primary completion until close to when the filing window opens, putting execution timing at the center of the story.
The patch already produced a positive Phase 3 result in older children, so the toddler filing rests on extending an established mechanism rather than proving a new one.
The sponsor has completed every prior trial in its portfolio without a termination, a record that speaks to operational discipline even though it says nothing about the toddler-specific safety data still to come.

The plan

DBV Technologies said it plans to submit a BLA for the Viaskin Peanut Patch in toddlers aged 1 through 3 in the second half of 2026, pursuing an accelerated approval pathway. The company reiterated the plan in disclosures tied to both its full-year 2025 results and its first-quarter 2026 update, with the filing window running from July 1 through December 31, 2026. CEO Daniel Tassé said the company entered 2025 with a goal of "preparing for the BLA submission and commercialization of the VIASKIN Peanut Patch in the United States, if approved," and has since added a chief commercial officer and a chief human resources officer ahead of a potential launch. DBV

Probability of Success

Endpoint Met65%

Completes67%

Clinical Significance25%

Regulatory82%

The supporting trial

The filing is supported by COMFORT Toddlers (NCT07003919), a Phase 3 safety study whose primary endpoint is the incidence of adverse events, treatment-emergent adverse events and serious adverse events during a double-blind, placebo-controlled treatment period, not an efficacy measure. The trial is recruiting toward 480 patients across sites in the United States, Canada, the United Kingdom, Australia, France, Spain, Ireland and the Netherlands, with a primary completion date of November 1, 2026. Enrollment has held flat at its 480-patient target with no protocol amendments to the primary endpoint after initiation, a pattern the operational model treats as routine rather than a signal of distress. NCT07003919

What the trial can establish

Because the primary endpoint is safety, not efficacy, the trial's information value lies in whether the patch's tolerability profile in 1-to-3-year-olds matches what DBV has already shown in older children, rather than in a new efficacy claim. The design is a randomized, placebo-controlled study with two active arms and one placebo arm, built to characterize adverse-event rates in a population whose skin and immune systems differ from the 4-to-7-year-old cohort DBV has already tested. NCT07003919

Same-drug precedent

DBV's Viaskin Peanut mechanism already cleared a Phase 3 readout in older children: the company reported positive topline results from the Phase 3 VITESSE trial in peanut-allergic children aged 4 to 7 in December 2025. That result gives the toddler program a same-drug precedent to build on, so the bar for the toddler filing is less about proving the epicutaneous immunotherapy mechanism works at all and more about reproducing an acceptable safety profile in a younger, more vulnerable age band. DBV's own registry lists ten prior Phase 3-caliber Viaskin Peanut trials in peanut allergy, underscoring how much of this program's history is generated by the same sponsor testing the same modality across age groups. DBV

The competitive field

Peanut allergy has an active but mechanistically varied set of programs: oral immunotherapy candidates like Aimmune's AR101, biologics such as Regeneron's dupilumab and Novartis's ligelizumab targeting IgE or IL-4 receptor alpha, and earlier-stage epicutaneous and immunotherapeutic entrants including Aravax's PVX108 and Ukko's UKK-0018. None of these share DBV's specific epicutaneous immunotherapy route with an identical mechanism profile, leaving Viaskin Peanut's own prior Phase 3 program, not an external rival, as the closest precedent for what a toddler-safety filing needs to show.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.